CLINICAL TRIALS PROFILE FOR BENICAR
✉ Email this page to a colleague
All Clinical Trials for BENICAR
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00122447 ↗ | Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance | Completed | Daiichi Sankyo Inc. | N/A | 2005-05-01 | The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial. |
NCT00122447 ↗ | Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance | Completed | Daiichi Sankyo, Inc. | N/A | 2005-05-01 | The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial. |
NCT00122447 ↗ | Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance | Completed | National Center for Research Resources (NCRR) | N/A | 2005-05-01 | The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial. |
NCT00122447 ↗ | Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | N/A | 2005-05-01 | The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial. |
NCT00122447 ↗ | Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance | Completed | Emory University | N/A | 2005-05-01 | The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial. |
NCT00185068 ↗ | An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension | Completed | Daiichi Sankyo Inc. | Phase 4 | 2004-03-01 | Effect of increasing doses of olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide on blood pressure in patients with hypertension |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BENICAR
Condition Name
Clinical Trial Locations for BENICAR
Trials by Country
Clinical Trial Progress for BENICAR
Clinical Trial Phase
Clinical Trial Sponsors for BENICAR
Sponsor Name